Trial Profile
A Randomized 26-Week Placebo-Controlled Efficacy and Safety Study With a 26-Week Long-Term Safety Extension of High- and Medium-Dose Inhaled Mometasone Furoate/Formoterol Fixed-Dose Combination Formulation Compared With Formoterol and High-Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Apr 2022
Price :
$35
*
At a glance
- Drugs Mometasone/formoterol (Primary) ; Formoterol; Mometasone
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics; Registrational; Therapeutic Use
- Sponsors Organon
- 06 Mar 2012 Results presented at the 68th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
- 24 Oct 2011 Results from this trial were presented at the 77th Annual Meeting of the American College of Chest Physicians, according to a Merck media release.
- 25 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.